ArticleThe Journal of antibiotics2026
The undiscovered natural product potential of Actinomycetes.
Article in The Journal of antibiotics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Large-scale discovery platform enables identification of peptides targeting drug-resistant candidiasis.Cell reports methods · 2026Article
- When context matters: community and environmental context to elicit natural products.Essays in biochemistry · 2026Review
- Intra- and inter-biosynthetic gene cluster allelic variation as drivers of chemical diversification in Streptomyces.Essays in biochemistry · 2026Review
- A foundation model enables prediction of natural product molecular properties, bioactivity, and structural similarity from biosynthetic gene cluster sequence.bioRxiv : the preprint server for biology · 2026Article
- Cebulactam AMarine drugs · 2026Article
- From Molecules to Metabolomes, Understanding Symbiosis through Small Molecules.Journal of natural products · 2026Review
- Community Curation of Microbial Metabolites Enables Biological Insights of Metabolomics Data.bioRxiv : the preprint server for biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
Actinomycetes have been a cornerstone species for the discovery of bioactive natural products with applications in pharmacotherapy and biotechnology. To expand the experimental evidence of their biosynthetic potential, we collected liquid-chromatography mass spectrometry untargeted metabolomics data on 948 microbial strains, mostly from Actinomycetes. This resulted in nearly two million MS/MS spectra, with an annotation rate of 13.3% corresponding to 2352 annotated molecules. Despite the efforts to link biosynthetic gene clusters to known molecules, most remain uncharacterized. This highlights the need for metabolomic data to bridge the gap between genomic potential and metabolite production. Although many unannotated spectra might correspond to different ion forms of the same molecule, the large amount of unknown molecules present in these datasets indicates that a significant number of natural products remain to be discovered, even within one of the most thoroughly studied sets of organisms. We provide a large metabolomics dataset as a public resource for data mining of microbial molecules and highlight its value by demonstrating the detection of edapochelins, recently discovered non-ribosomal peptides.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.